Please assess the completion status of the following clinical trial:

Trial Title: Supplements, Placebo, or Rosuvastatin Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained before any assessment is performed.~2. U.S. adults with primary hypercholesterolemia, 40-75 years of age.~3. Not currently taking statins or one of the dietary supplements included in the trial. Patients willing to discontinue a prohibited supplement for 4 weeks prior to enrollment will be allowed to participate.~4. LDL-cholesterol between 70 and 189 mg/dL.~5. Patients without diabetes mellitus and a 10-year risk of ASCVD between 5 and \<20% using the pooled cohort risk equation. \* Or Patients with diabetes mellitus in females 50-60 years of age or males 40-50 years of age with an LDL-C between 70-189 mg/dL and with an ASCVD risk below 20%.~Exclusion Criteria:~1. Age \< 40 or \>75 years of age~2. Women who are pregnant, plan to become pregnant within the next 6 months, or are breastfeeding.~3. Documented liver dysfunction or history of elevated LFTs indicating active liver disease~4. Documented chronic renal dysfunction within the past two years defined as an eGFR\<30mL/min/m2.~5. Known hypersensitivity to rosuvastatin or any supplement under investigation (i.e. shellfish allergy, etc.).~6. Currently taking any prescription statin, or other prescription medication/supplements to treat elevated cholesterol or triglycerides.~7. Currently taking a medication/supplement that has known interaction with rosuvastatin, including fenofibrate, gemfibrozil, HIV medications, colchicine, cyclosporine, warfarin, anti-viral medications to treat Hepatitis C, regorafenib, and darolutamide.~8. Are unwilling to discontinue prohibited dietary supplement(s) for 4 weeks prior to participation or during the course of the trial. Other non-prohibited supplements will be permitted if doses have been stable for at least 4 weeks.~9. Known cardiovascular disease including a history of prior MI, stroke/TIA, PAD or prior revascularization procedures of the heart or vasculature (e.g. CABG, stenting, PCI etc.).~10. Fasting Triglycerides \>200mg/dl.~11. In the opinion of the investigator, any other condition that will preclude participation in the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: ACTIVE_COMPARATOR): 5 mg once per day
- Placebo (Type: PLACEBO_COMPARATOR): comparable to rosuvastatin 5 mg once per day
- Fish Oil (Type: ACTIVE_COMPARATOR): Nature Made 2 soft gels per day
- Cinnamon (Type: ACTIVE_COMPARATOR): 1200mg, 2 capsules per day
- Garlique (Type: ACTIVE_COMPARATOR): Manufactured by Focus Consumer Health Marketgate,1 tablet per day
- Turmeric (Type: ACTIVE_COMPARATOR): Bio Schwartz Turmeric Curcumin 1500 mg, 3 capsules per day
- Plant Sterol (Type: ACTIVE_COMPARATOR): Nature Made CholestOff Plus, 2 soft gels twice a day
- Red Yeast Rice (Type: ACTIVE_COMPARATOR): Arazo Nutrition 1200 mg, 2 capsules per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete